Study on correlation between serum bilirubin level and carotid plaque in type 2 diabetes mellitus

doi:10.3969/j.issn.1004-583X.2021.04.010

Abstract

Abstract:

Objective To explore the correlation between serum bilirubin level and carotid plaque formation in type 2 diabetes mellitus. Methods Nine hundred and fifty two hospitalized patients with type 2 diabetes were selected, and the patients were divided into 426 patients with carotid plaque (plaque group) and 526 patients without carotid plaque (non-plaque group) according to the results of carotid artery color ultrasonography. The essential information and data including the serum bilirubin level, blood glucose, blood lipids, glycated hemoglobin, etc. were recorded, and related factors affecting the formation of carotid plaque were studied. Results Compared to the patients in non-plaque group, the patients in the plaque group were featured with more males, older age, longer course of disease, longer combined history of smoking and hypertension, lower total bilirubin(TBIL) and indirect bilirubin(IBIL) levels, higher serum creatinine(Scr) and greater total cholesterol(TCHO) and low-density lipoprotein cholesterol(LDL-C) levels(P<0.05). The gender, age, course of disease, smoking history were considered to be independent risk factors of carotid plaque, and indirect bilirubin was considered to be a protective factor for carotid plaque. Conclusion The level of serum indirect bilirubin is independently correlated with the risk of carotid plaque when the serum total bilirubin level is within the physiological range.

Key words: diabetes, type 2, bilirubin, carotid plaque

CLC Number:

R587.1

Jin Hui, Liu Shangquan. Study on correlation between serum bilirubin level and carotid plaque in type 2 diabetes mellitus[J]. Clinical Focus, 2021, 36(4): 340-343.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.04.010

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I4/340

Figures/Tables 2

References 29

[1]	Gazzin S, Vitek L, Watchko J, et al. A novel perspective on the biology of bilirubin in health and disease[J]. Trends Mol Med, 2016,22(9):758-768. doi: 10.1016/j.molmed.2016.07.004 URL
[2]	Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998,15(7):539-553. doi: 10.1002/(ISSN)1096-9136 URL
[3]	Kumar A, Pant P, Basu S, et al. Oxidative stress in neonatal hyperbilirubinemia[J]. J Trop Pediatr, 2007,53(1):69-71. doi: 10.1093/tropej/fml060 URL
[4]	Hwang HJ, Lee SW, Kim SH. Relationship between bilirubin and C-reactive protein[J]. Clin Chem Lab Med, 2011,49(11):1823-1828.
[5]	Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome[J]. Circulation, 2012,126(5):598-603. doi: 10.1161/CIRCULATIONAHA.112.105775 URL
[6]	Mahabadi AA, Lehmann N, Mohlenkamp S, et al. Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: The Heinz Nixdorf Recall study[J]. Clin Res Cardiol, 2014,103:647-653. doi: 10.1007/s00392-014-0697-z pmid: 24633678
[7]	Hamoud AR, Weaver L, Stec DE, et al. Bilirubin in the Liver-Gut Signaling Axis[J]. Trends Endocrinol Metab, 2018,29(3):140-150. doi: 10.1016/j.tem.2018.01.002 URL
[8]	Ong KL, Allison MA, Cheung BM, et al. The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004[J]. PLoS One, 2014,9(4):e94479. doi: 10.1371/journal.pone.0094479 URL
[9]	Chen SC, Lin CP, Hsu HC, et al. Serum bilirubin improves the risk predictions of cardiovascular and total death in diabetic patients[J]. Clin Chim Acta, 2019,488:1-6. doi: 10.1016/j.cca.2018.10.028 URL
[10]	Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort[J]. Circulation, 2012,126:2556-2564. doi: 10.1161/CIRCULATIONAHA.112.114066 pmid: 23110860
[11]	Lai X, Fang Q, Yang L, et al. Direct, indirect and total bilirubin and risk of incident coronary heart disease in the Dongfeng-Tongji cohort[J]. Ann Med, 2018,50(1):16-25. doi: 10.1080/07853890.2017.1377846 URL
[12]	Chung JO, Park SY, Cho DH, et al. Anemia, bilirubin, and cardiovascular autonomic neuropathy in patients with type 2 diabetes[J]. Medicine (Baltimore), 2017,96(15):e6586. doi: 10.1097/MD.0000000000006586 URL
[13]	Ghaffar T, Marwat ZI, Ullah F, et al. Association of serum total bilirubin level with diabetic retinopathy in type 2 diabetes mellitus[J]. J Ayub Med Coll Abbottabad, 2016,28(3):537-541.
[14]	吕波. 血清胆红素和胱抑素C水平与糖尿病视网膜病变的相关性研究[J]. 中国医药指南, 2020,18(5):117-118.
[15]	佟晶晶, 施克新, 冷飞, 等. 血清胆红素水平与2型糖尿病视网膜病变的相关性[J]. 临床荟萃, 2020,35(9):816-822.
[16]	Yan P, Zhang Z, Miao Y, et al. Physiological serum total bilirubin concentrations were inversely associated with diabetic peripheral neuropathy in Chinese patients with type 2 diabetes: a cross-sectional study[J]. Diabetol Metab Syndr, 2019,11:100. doi: 10.1186/s13098-019-0498-7 URL
[17]	董越华, 董计东, 辛欢欢, 等. 2型糖尿病患者颈动脉粥样硬化与血清胆红素水平的相关性[J]. 心脑血管病防治, 2018,18(5):379-381.
[18]	商书霞, 宋光耀, 赵军魁, 等. 血清胆红素水平与2型糖尿病患者下肢动脉病变的相关性研究[J]. 河北医科大学学报, 2017,38(3):339-343.
[19]	Inoue T, Sonoda N, Hiramatsu S, et al. Serum bilirubin concentration is associated with left ventricular remodeling in patients with type 2 diabetes mellitus: A cohort study[J]. Diabetes Ther, 2018,9(1):331-338. doi: 10.1007/s13300-018-0368-6 URL
[20]	Yang M, Ni C, Chang B, et al. Association between serum total bilirubin levels and the risk of type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2019,152:23-28. doi: 10.1016/j.diabres.2019.04.033 URL
[21]	Kwon YJ, Lee YJ, Park BJ, et al. Total serum bilirubin and 8-year incident type 2 diabetes mellitus: The Korean Genome and Epidemiology Study[J]. Diabetes Metab, 2018,44(4):346-353. doi: 10.1016/j.diabet.2017.07.004 URL
[22]	Nishimura T, Tanaka M, Saisho Y, et al. Lower serum total bilirubin concentration is associated with higher prevalence of gestational diabetes mellitus in Japanese pregnant women[J]. Endocr J, 2018,65(12):1199-1208. doi: 10.1507/endocrj.EJ17-0533 URL
[23]	刘靖. 妊娠糖尿病患者血清胆红素、丙二醛水平与糖代谢及不良妊娠结局的相关性研究[D]. 桂林医学院, 2019.
[24]	董丽, 杨丽霞, 郭海霞, 等. 孕期血清胆红素水平与妊娠期糖尿病的相关性研究[J]. 中国医刊, 2017,52(5):90-93.
[25]	Inoguchi T, Fukuhara S, Yamato M, et al. Serum bilirubin level is a strong predictor for disability in activities in daily living (ADL) in Japanese elderly patients with diabetes[J]. Sci Rep, 2019,9(1):7069. doi: 10.1038/s41598-019-43543-6 URL
[26]	高爱滨, 魏兆丽. 老年2型糖尿病肾病患者血清胆红素、胱抑素C水平变化及意义[J]. 山东医药, 2017,57(14):63-65.
[27]	章紫晨, 葛声. 1型糖尿病患者血清胆红素水平与亚临床动脉粥样硬化的关系[J]. 中华健康管理学杂志, 2018,12(5):457-460.
[28]	李丹, 汲宝兰, 班博, 等. 2型糖尿病患者血清胆红素水平与糖尿病视网膜病变的相关性研究[J]. 中华内分泌代谢杂志, 2020, (3):227-234.
[29]	任丽燕. 血清胆红素水平与2型糖尿病血管病变相关性的研究[J]. 中国现代医生, 2018,56(18):8-11.

项目	斑块组(n=426)	无斑块组(n=526)	统计值(t/Z/χ²)	P值
男/(例)	246(57.7)	257(48.9)	7.460	0.006
年龄(岁)	60(53,66)	54(48,60)	-9.583	<0.01
BMI(kg/m²)	24.19(22.49,26.33)	24.59(22.66,27.02)	-1.701	0.089
病程(月)	84(36,132)	48(12,96)	-5.476	<0.01
吸烟史(例)	152(35.7)	126(24.0)	15.655	<0.01
饮酒史(例)	61(14.3)	54(10.3)	3.641	0.056
糖尿病家族史(例)	165(38.7)	220(41.8)	0.935	0.334
高血压病史(例)	211(49.5)	199(37.8)	13.136	<0.01
ALB(g/L)	42.57±3.32	42.83±3.30	1.179	0.239
TBIL(μmol/L)	12.6(10.5,15.6)	13.5(10.6,16.4)	-2.262	0.024
DBIL(μmol/L)	4.4(3.5,5.5)	4.4(3.4,5.5)	-0.169	0.865
IBIL(μmol/L)	8.4(6.4,10.1)	8.9(6.9,10.9)	-3.018	0.003
ALT(U/L)	21.1(15.1,29.2)	21.0(14.9,31.2)	-0.489	0.625
AST(U/L)	19.3(16.0,24.0)	19.4(16.1,25.3)	-1.151	0.250
Urea(mmol/L)	5.15(4.30,6.22)	4.99(4.30,6.03)	-0.922	0.356
Scr(μmol/L)	62.1(51.7,72.2)	59.0(49.0,70.4)	-2.556	0.011
TG(mmol/L)	1.74(1.21,2.50)	1.81(1.23,2.59)	-0.442	0.658
CHO(mmol/L)	4.94(4.35,5.68)	4.82(4.19,5.51)	-1.973	0.048
LDL-C(mmol/L)	2.88±0.81	2.74±0.79	-2.733	0.006
HDL-C(mmol/L)	1.28(1.05,1.52)	1.28(1.06,1.52)	-0.283	0.777
Hb(g/L)	139.19±15.06	139.43±14.23	0.254	0.799
HbA₁c(%)	8.9(7.4,10.8)	8.9(7.5,10.9)	-0.136	0.891
FPG(mmol/L)	9.45(7.36,12.09)	9.37(7.50,12.39)	-1.157	0.247

项目	斑块组(n=426)	无斑块组(n=526)	统计值(t/Z/χ²)	P值
男/(例)	246(57.7)	257(48.9)	7.460	0.006
年龄(岁)	60(53,66)	54(48,60)	-9.583	<0.01
BMI(kg/m²)	24.19(22.49,26.33)	24.59(22.66,27.02)	-1.701	0.089
病程(月)	84(36,132)	48(12,96)	-5.476	<0.01
吸烟史(例)	152(35.7)	126(24.0)	15.655	<0.01
饮酒史(例)	61(14.3)	54(10.3)	3.641	0.056
糖尿病家族史(例)	165(38.7)	220(41.8)	0.935	0.334
高血压病史(例)	211(49.5)	199(37.8)	13.136	<0.01
ALB(g/L)	42.57±3.32	42.83±3.30	1.179	0.239
TBIL(μmol/L)	12.6(10.5,15.6)	13.5(10.6,16.4)	-2.262	0.024
DBIL(μmol/L)	4.4(3.5,5.5)	4.4(3.4,5.5)	-0.169	0.865
IBIL(μmol/L)	8.4(6.4,10.1)	8.9(6.9,10.9)	-3.018	0.003
ALT(U/L)	21.1(15.1,29.2)	21.0(14.9,31.2)	-0.489	0.625
AST(U/L)	19.3(16.0,24.0)	19.4(16.1,25.3)	-1.151	0.250
Urea(mmol/L)	5.15(4.30,6.22)	4.99(4.30,6.03)	-0.922	0.356
Scr(μmol/L)	62.1(51.7,72.2)	59.0(49.0,70.4)	-2.556	0.011
TG(mmol/L)	1.74(1.21,2.50)	1.81(1.23,2.59)	-0.442	0.658
CHO(mmol/L)	4.94(4.35,5.68)	4.82(4.19,5.51)	-1.973	0.048
LDL-C(mmol/L)	2.88±0.81	2.74±0.79	-2.733	0.006
HDL-C(mmol/L)	1.28(1.05,1.52)	1.28(1.06,1.52)	-0.283	0.777
Hb(g/L)	139.19±15.06	139.43±14.23	0.254	0.799
HbA₁c(%)	8.9(7.4,10.8)	8.9(7.5,10.9)	-0.136	0.891
FPG(mmol/L)	9.45(7.36,12.09)	9.37(7.50,12.39)	-1.157	0.247

变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
变量	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
男性	0.418	0.176	5.646	0.017	1.519	1.076	2.145
年龄(岁)	0.085	0.009	84.045	0.000	1.089	1.069	1.108
病程(月)	0.003	0.001	8.264	0.004	1.003	1.001	1.006
有吸烟史	0.626	0.192	10.670	0.001	1.870	1.285	2.723
IBIL(μmol/L)	-0.081	0.026	9.495	0.002	0.922	0.876	0.971

变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
变量	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
男性	0.418	0.176	5.646	0.017	1.519	1.076	2.145
年龄(岁)	0.085	0.009	84.045	0.000	1.089	1.069	1.108
病程(月)	0.003	0.001	8.264	0.004	1.003	1.001	1.006
有吸烟史	0.626	0.192	10.670	0.001	1.870	1.285	2.723
IBIL(μmol/L)	-0.081	0.026	9.495	0.002	0.922	0.876	0.971